BRCA-associated ovarian cancer (the experience of the Chemotherapy Department in N.N.Blokhin Russian Cancer Research Center of the Ministry of Health of Russia)
- Authors: Khokhlova SV1, Gorbunova VA1, Lyubchenko LN1, Imyanitov EN2
-
Affiliations:
- N.N.Blokhin Russian Cancer Research Center of the Ministry of Health of the Russian Federation
- N.N.Petrov Research Institute of Oncology of the Ministry of Health of the Russian Federation
- Issue: Vol 18, No 1 (2016)
- Pages: 37-44
- Section: Articles
- URL: https://journals.rcsi.science/1815-1434/article/view/27050
- ID: 27050
Cite item
Full Text
Abstract
Keywords
Full Text
##article.viewOnOriginalSite##About the authors
S V Khokhlova
N.N.Blokhin Russian Cancer Research Center of the Ministry of Health of the Russian Federation
Email: SVKhokhlova@mail.ru
д-р мед. наук, ст. науч. сотр. отд-ния химиотерапии ФГБУ РОНЦ им. Н.Н.Блохина 115478, Russian Federation, Moscow, Kashirskoe sh., d. 23
V A Gorbunova
N.N.Blokhin Russian Cancer Research Center of the Ministry of Health of the Russian Federationд-р мед. наук, проф., зав. отд-нием химиотерапии ФГБУ РОНЦ им. Н.Н.Блохина 115478, Russian Federation, Moscow, Kashirskoe sh., d. 23
L N Lyubchenko
N.N.Blokhin Russian Cancer Research Center of the Ministry of Health of the Russian Federationд-р мед. наук, рук. лаб. клин. онкогенетики ФГБУ РОНЦ им. Н.Н.Блохина 115478, Russian Federation, Moscow, Kashirskoe sh., d. 23
E N Imyanitov
N.N.Petrov Research Institute of Oncology of the Ministry of Health of the Russian Federationд-р мед. наук, проф., рук. лаб. молекулярной онкологии ФГБУ НИИО им. Н.Н.Петрова 197758, Russian Federation, Saint Petersburg, pos. Pesochnyi, ul. Leningradskaia, d. 68
References
- Давыдов М.И., Аксель Е.М. Статистика злокачественных новообразований в России и странах СНГ в 2012 г. Вестн. Российского онкологического научного центра им. Н.Н.Блохина РАМН. 2013; 22 (3): 9-142.
- Имянитов Е.Н. Общие представления о наследственных опухолевых синдромах. Практическая онкология. 2014; 15 (3): 101.
- Максимов С.Я., Имянитов Е.Н. и др. Клинические особенности BRCA-позитивного рака яичников. Сиб. онкологический журн. 2013; 6 (60).
- Мамедов В.А., Бахидзе Е.В., Имянитов Е.Н. Оценка эффективности лекарственного лечения у больных раком яичников с различным статусом гена BRCA. Сиб. онкологический журн. 2009; S1: 129-30.
- Смирнова Т.Ю., Поспехова Н.И., Любченко Л.Н. и др. Высокая частота мутаций в генах BRCA1 и BRCA2 при раке. Бюлл. эксперимент. биологии и медицины. 2007; 144 (7): 93-5.
- Fedorova O.E, Liubchenko L.N, Paiadini Iu.G et al. Analysis of BRCA1/2 and CHEK2 mutations in ovarian cancer and priary multiple tumors involving the ovaries. Patients of Russian population using biochips. Mol Biol (Mosk) 2007; 41: 37.
- Imyanitov E.N, Byrski T. Systemic treatment for hereditary cancers: a 2012 update. Hered Cancer Clin Pract 2013; 11 (1): 2. doi: 10.1186/1897-4287-11-2.
- Imyanitov E.N. Ovarian cancer genome. Methods Mol Biol 2013; 1049: 3-7.
- Imyanitov E.N, Moiseyenko V.M. Drug therapy for hereditary cancers. Hered Cancer Clin Pract 2011; 9 (1): 5. doi: 10.1186/1897-4287-9-5.
- Armstrong D.K et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. New En J Med 2006; 354 (1): 34-43.
- Bolton K, Chenevix-Trench G et al. Association between BRCA1 and BRCA2 Mutations and Survival in women with Invasive Epithelial Ovarian Cancer. JAMA 2012; 307 (4): 382-90.
- Boyd J, Sonoda Y, Federici M.G et al. Clinicopathologic features of BRCA-linked and sporadic ovarian cancer. JAMA 2000; 283 (17): 2260-5.
- Cass I, Baldwin R et al. Improved Survival in women with BRCA-associated Ovarian carcinoma. Am Cancer Soc 2003; 97 (9).
- Chan J.K, Tian C, Monk B.J et al. Prognostic factors for high - risk early - stage epithelial ovarian cancer: a Gynecologic Oncology Group study. Cancer 2008; 112 (10: 2202-10.
- Deng C.X, Brodie S.G. Role of BRCA 1 and its interacting proteins. Bioessays 2010; 22 (8): 728-37.
- Farmer H, Mc Cabe N, Lord C.J et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005; 434 (7035): 917-21.
- Karami F, Mehdipour P. A comprehensive focus on global spectrum of BRCA1 and BRCA2 mutations in breast cancer. Biomed Res Int 2013; c. 928562.
- Lesnock J.L et al. BRCA1 expression and improved survival in ovarian cancer patients treated with intraperitoneal cisplatin and paclitaxel: a Gynecologic Oncology Group Study. Br J Cancer 2013; 108 (6): 1231-7.
- Leunen K et al. Does paclitaxel - carboplatin chemotherapy in a dose - dense regimen enhance survival of BRCA-related ovarian cancer patients? Intl J Gynecologic Cancer 2009; 19 (9): 1501-4.
- Parvin J.D. BRCA 1 at a branch point. Proc Natl Acad Dci USA 2001; 98 (11): 5952-4.
- Rubin S.C, Benjamin I, Behbakht K et al. Clinical and pathological features of ovarian cancer in women with germ - line mutations of BRCA1. N Engl J Med 1996; 335 (19): 1413-6.
- Safra T, Rogowski O, Muggia F.M. The effect of germ - line BRCA mutations on response to chemotherapy and outcome of recurrent ovarian cancer. Int J Gynecologic Cancer 2014; 24 (3): 488-95.
- Yang D. Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer. JAMA 2011; 306 (14): 1557-65.
- Yang D, Khan S, Sun Y et al. Association between BRCA2 but not BRCA1 mutations and beneficial Survival, Chemotherapy sensitivy, and gene Mutator Phenotype in Patients with ovarian cancer. JAMA 2011; 306 (14): 1557-65.
- Zhong Q, Peng H et al. Effects of BRCA1-and BRCA2-related Mutations on Ovarian and Breast Cancer Survival: A Meta - analysis. Clin Cancer Res 2014; 21 (1): 211-20.
- Ashworth A et al. A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double - strand break repair. J Clin Oncol 2008; 26: 3785-90.
- Mc Cabe N, Turner N.C, Lord C.J et al. Deficiency in the repair of DNA damage by homologous recombination and sensitivity to Poly(ADP-Ribose) polymerase inhibition. Cancer Res 2006; 66: 8109-15.
- Audeh M.W et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof - of - concept trial. Lancet 2010; 376: 245-51.
- Ledermann J, Harter P. Olaparib maintenance therapy in patients with platinum - sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancel. Published Online May 30, 2014 http://dx.doi.org/10.1016/ S1470-2045(14)70228-1